Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
SC Pembrolizumab: IV Non-Inferiority, Patient Convenience
The KEYNOTE-A18 trial is a Phase 3, randomized, non-inferiority study assessing subcutaneous (SC) pembrolizumab (MK- 3475A with hyaluronidase) versus intravenous (IV) pembrolizumab for advanced melanoma, NSCLC, RCC, HNSCC, and UC. It enrolled 1756 patients, comparing 600 mg SC Q6W with standard IV dosing. Primary endpoints include PK equivalence (C... Read More»
: J Infect Pathol 08: 314
Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals